xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

552

INTERNATIONAL CONSENSUS ON OLFACTION

TABLE IX-3 (Continued) Study Year

LOE Study design Study groups

Clinical end point VAS (0–10) Data collection points: week 1, week 2, week 4, week 8, week 12

Conclusions

Compared with placebo, themethyl prednisolone group demonstrated significantly greater improvement in VAS at week 1, week 2, and week4 Compared with baseline, only the oral prednisone group demonstrated a significant improvement in subjective symptom score at week 2 This was not sustained at week 12 Compared with baseline, only the prednisone group demonstrated significant improvement in VAS at week2 Compared with baseline, only the prednisone group demonstrated a significant improvement in subjective symptom score at week 12, week 24, and week 48 Compared with baseline, subjective symptom scores improved significantly in both the methylprednisolone groups and topical furosemide groups at week 1 No significant difference Compared with baseline, only oral prednisolone group demonstrated significantly improvement in subjective smell at week2 was seen in values posttreatment when comparing groups

VanZele et al 1380

2010 2

RCT

CRSwNP (N = 47) Oral methylpred nisolone 32 mg taper × 20days (n = 14) Placebo × 20days (n = 19) CRSwNP (N = 84) Oral prednisone 30 mg once daily taper × 2weeks + budesonide 400 μ g twice daily × 10 weeks (n = 63) No treatment (n = 21) mg once daily × 14 days + ESS (n = 11) Placebo + ESS (n = 15) CRSwNP (N = 78) Oral prednisone 30 mg taper × 2weeks + budesonide 400 μ g × 48weeks (n = 60) No treatment (n = 18) CRSwNP (N = 40) Oral methylpednisolone (1 mg/kg/day) × 7 days (n = 20) Nasal furosemide (6.6 mmol/1 solution) (n = 20) CRSwNP (N = 26) Oral prednisone 30

Benitez

2006

2

RCT

Subjective symptom score (0–3) Data collection points: week 2, week 12

et al 1381

Wright

VAS (0–10) Data collection points: week 2, week 4, week 12,week24

2007

2

RCT

et al 1382

Alobid

2006

2

Controlled clinical

Subjective symptom score (0–3) Data collection points: week 12, week 24, week48

et al 1383

Kroflic

Subjective symptom score (0–3) Data collection point: week 1

2006

2

Randomized

et al 1384

comparative

Hissaria

2006

2

RCT

CRSwNP (N = 40) Oral prednisolone 50 mg once daily × 14 days (n = 20) Placebo × 14days (n = 20)

RSOM-31 (individual smell question) Data collection points: week2

et al 1385

BAST = Barcelona Smell Test; BTT = Butanol Threshold Test; CRSwNP = chronic rhinosinusitis with nasal polyps; ESS = endoscopic sinus surgery; FP = flutica sone propionate; LOE = level of evidence; MF = mometasone furoate; NS = nasal spray; PST = Pocket Smell Test; RCT = randomized controlled trial; RSOM-31 = 31-item rhinosinusitis outcome measure; VAS = visual analog scale.